With $550 million in facility-specific investment and 355 permanent operating jobs announced, this project clears both of AFT's qualifying thresholds ($100 million in facility-specific investment OR 100 permanent operating jobs). It is also confirmed by official public sources and involves a physical manufacturing facility in the United States.
View full methodology →The pharmaceuticals context.
Pharmaceutical manufacturers are committing billions to new U.S. production capacity for active ingredients, injectable medicines, biologics and other high-demand treatments. North Carolina and Indiana remain major centers of investment, while new facilities are being planned across the South. The current project pipeline includes both large greenfield campuses and major expansions of established production sites.
At a glance
- Company
- Amgen (Holly Springs)
- Industry
- Pharmaceuticals
- Location
- Holly Springs, North Carolina
- Investment
- $550.0M
- Permanent jobs announced
- 355
- Status
- Operational
- Announced
- Aug 3, 2021
- Operations began
- Jan 1, 2025
- Added to tracker
- Feb 25, 2026
Official references
- North Carolina Commerce and Amgen's August 3, 2021 Holly Springs announcement https://www.commerce.nc.gov/news/press-releases/governor-cooper-announces-amgen-will-create-355-jobs-new-biomanufacturing
Cite this project
American Factory Tracker. "Holly Springs Drug-Substance Biomanufacturing Facility (Initial Phase) — Amgen, Holly Springs, NC." https://americanfactorytracker.com/projects/amgen-holly-springs-holly-springs. Accessed November 6, 2026.
Please also cite the original sources listed above for underlying figures.